Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial

The clinical benefit of eribulin versus capecitabine was evaluated using health-related quality of life (HRQoL) data from a phase 3 randomized trial in patients with pretreated advanced/metastatic breast cancer (ClinicalTrials.gov identifier: NCT00337103). The study population has been described pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Cortes, Javier, Hudgens, Stacie, Twelves, Chris, Perez, Edith A., Awada, Ahmad, Yelle, Louise, McCutcheon, Susan, Kaufman, Peter A., Forsythe, Anna, Velikova, Galina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2015
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4661183/
https://www.ncbi.nlm.nih.gov/pubmed/26567010
http://dx.doi.org/10.1007/s10549-015-3633-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4661183/
https://www.ncbi.nlm.nih.gov/pubmed/26567010
http://dx.doi.org/10.1007/s10549-015-3633-7

Ejemplares similares